Within the last years (89)Zr has attracted considerable attention as long-lived radionuclide for positron emission tomography (PET) applications. So far desferrioxamine B (DFO) has been mainly used as bifunctional chelating system. Fusarinine C (FSC), having complexing properties comparable to DFO, was expected to be an alternative with potentially higher stability due to its cyclic structure. In this study, as proof of principle, various FSC-RGD conjugates targeting αvß3 integrins were synthesized using different conjugation strategies and labeled with (89)Zr. In vitro stability, biodistribution, and microPET/CT imaging were evaluated using [(89)Zr]FSC-RGD conjugates or [(89)Zr]triacetylfusarinine C (TAFC). Quantitative (89)Zr labeling was achieved within 90 min at room temperature. The distribution coefficients of the different radioligands indicate hydrophilic character. Compared to [(89)Zr]DFO, [(89)Zr]FSC derivatives showed excellent in vitro stability and resistance against transchelation in phosphate buffered saline (PBS), ethylenediaminetetraacetic acid solution (EDTA), and human serum for up to 7 days. Cell binding studies and biodistribution as well as microPET/CT imaging experiments showed efficient receptor-specific targeting of [(89)Zr]FSC-RGD conjugates. No bone uptake was observed analyzing PET images indicating high in vivo stability. These findings indicate that FSC is a highly promising chelator for the development of (89)Zr-based PET imaging agents.

§Division of Molecular Biology Medical University Innsbruck Innsbruck Austria

†Department of Nuclear Medicine Medical University Innsbruck Innsbruck Austria

∥Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Fischer G.; Seibold U.; Schirrmacher R.; Wangler B.; Wangler C. PubMed PMC

Deri M. A.; Zeglis B. M.; Francesconi L. C.; Lewis J. S. PET imaging with PubMed PMC

Chang A. J.; DeSilva R.; Jain S.; Lears K.; Rogers B.; Lapi S. PubMed PMC

Aerts H. J.; Dubois L.; Perk L.; Vermaelen P.; van Dongen G. A.; Wouters B. G.; et al. Disparity between in vivo EGFR expression and PubMed

Holland J. P.; Divilov V.; Bander N. H.; Smith-Jones P. M.; Larson S. M.; Lewis J. S. PubMed PMC

Zeglis B. M.; Mohindra P.; Weissmann G. I.; Divilov V.; Hilderbrand S. A.; Weissleder R.; et al. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand diels–alder click chemistry. Bioconjugate Chem. 2011, 22, 2048–2059. PubMed PMC

van Rij C. M.; Sharkey R. M.; Goldenberg D. M.; Frielink C.; Molkenboer J. D.; Franssen G. M.; et al. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J. Nucl. Med. 2011, 52, 1601–1607. PubMed

Heskamp S.; van Laarhoven H. W.; Molkenboer-Kuenen J. D.; Franssen G. M.; Versleijen-Jonkers Y. M.; Oyen W. J.; et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med. 2010, 51, 1565–1572. PubMed

Perk L. R.; Vosjan M. J.; Visser G. W.; Budde M.; Jurek P.; Kiefer G. E.; et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 250–259. PubMed PMC

Tinianow J. N.; Gill H. S.; Ogasawara A.; Flores J. E.; Vanderbilt A. N.; Luis E.; et al. Site-specifically PubMed

Patra M.; Bauman A.; Mari C.; Fischer C. A.; Blacque O.; Häussinger D.; et al. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. Chem. Commun. 2014, 50, 11523–11525. PubMed

Deri M. A.; Ponnala S.; Zeglis B. M.; Pohl G.; Dannenberg J. J.; Lewis J. S.; et al. An alternative chelator for PubMed PMC

Guérard F.; Lee Y. S.; Brechbiel M. W. Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium (IV). Chemistry 2014, 20, 5584–5591. PubMed PMC

Pandya D. N.; Pailloux S.; Tatum D.; Magda D.; Wadas T. J. Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89. Chem. Commun. 2015, 51, 2301–2303. PubMed PMC

Ma M. T.; Meszaros L. K.; Paterson B. M.; Berry D. J.; Cooper M. S.; Ma Y. Tripodal tris (hydroxypyridinone) ligands for immunoconjugate PET imaging with PubMed PMC

Liu S.; Edwards D. S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 2001, 12, 7–34. PubMed

Knetsch P. A.; Zhai C.; Rangger C.; Blatzer M.; Haas H.; Kaeopookum P.; et al. [ PubMed PMC

Zhai C.; Summer D.; Rangger C.; Haas H.; Decristoforo C.; Fusarinine C. a fast, high specific activity, wide pH range, and stable multivalent bifunctional siderophore chelator for radiolabeling with gallium-68. J. Labelled Comp. Radiopharm. 2015, 58, 209–214. PubMed PMC

Petrik M., Zhai C., Novy Z., Urbanek L., Haas H., Decristoforo C.. In vitro and in vivo comparison of selected

Petrik M.; Haas H.; Schrettl M.; Helbok A.; Blatzer M.; Decristoforo C. In vitro and in vivo evaluation of selected PubMed PMC

Knetsch P. A.; Petrik M.; Griessinger C. M.; Rangger C.; Fani M.; Kesenheimer C.; et al. [ PubMed

Vosjan M. J.; Perk L. R.; Visser G. W.; Budde M.; Jurek P.; Kiefer G. E.; et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 2010, 5, 739–743. PubMed

Petrik M.; Haas H.; Dobrozemsky G.; Lass-Flörl C.; Helbok A.; Blatzer M.; et al. PubMed PMC

Haubner R.; Gratias R.; Diefenbach B.; Goodman S. L.; Jonczyk A.; Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin α

Haubner R.; Maschauer S.; Prante O. PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed. Res. Int. 2014, 871609. PubMed PMC

Haubner R.; Decristoforo C.; Radiolabelled R. G. D. peptides and peptidomimetics for tumour targeting. Front. Biosci. 2009, 14, 872–86. PubMed

Gaertner F. C.; Kessler H.; Wester H. J.; Schwaiger M.; Beer A. J. Radiolabelled RGD peptides for imaging and therapy. Eur. J. Nucl. Med. 2012, 39Suppl 1S126–S138. PubMed

Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin α PubMed

Dumont R. A.; Deininger F.; Haubner R.; Maecke H. R.; Weber W. A.; Fani M. Novel PubMed

Chen X.; Park R.; Tohme M.; Shahinian A. H.; Bading J. R.; Conti P. S. MicroPET and autoradiographic imaging of breast cancer α PubMed

Guérard F.; Lee Y.-S.; Tripier R.; Szajek L. P.; Deschamps J. R.; Brechbiel M. W. Investigation of Zr (IV) and PubMed PMC

Novel dimeric dual-modality FAP-targeted agents with favorable tumor retention for image-guided surgery: a preclinical study

Modifying the Siderophore Triacetylfusarinine C for Molecular Imaging of Fungal Infection

Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs

Siderophores for molecular imaging applications

Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding

Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors

In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores